PVLA
Palvella Therapeutics, Inc. trades as PVLA and has a market capitalization of $2.16 B, making it the #2076 largest US-listed company by market value. This page tracks Palvella Therapeutics, Inc. through 772 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Palvella Therapeutics, Inc.'s revenue grew from $5.37M to $42.81M, a compound annual growth rate of 26.0%. Net profit margin expanded from -391.0% to 43.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Major company event | 8-K | 2026-05-20 |
| Major company event | 8-K | 2026-05-15 |
| Major company event | 8-K | 2026-05-13 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-30 |
The largest companies sharing Palvella Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Palvella Therapeutics, Inc. (PVLA) has a market capitalization of $2.16 B as of 2026-07-09, ranking #2076 among US-listed companies.
In its latest fiscal year Palvella Therapeutics, Inc. reported a net loss of $41.72M.